Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis

Oncotarget

Volumn 8, Issue 3, 2017, Pages 4781-4795

  Huang, Xuan Zhang ^a   Chen, You ^b   Wu, Jian ^a   Zhang, Xi ^a   Wu, Cong Cong ^a   Zhang, Chao Ying ^a   Sun, Shuang Shuang ^a   Chen, Wen Jun ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b The Wenzhou Dental Hospital   (China)

Author keywords

Aspirin; Chemoprevention; Gastric cancer; Meta analysis; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CORRELATIONAL STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG USE; HUMAN; META ANALYSIS; RISK REDUCTION; STOMACH CANCER; TREATMENT DURATION; TREND STUDY; TUMOR LOCALIZATION; CARDIA; FEMALE; MALE; ODDS RATIO; PATHOLOGY; STOMACH TUMOR; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; ODDS RATIO; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 85012013259     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13591     Document Type: Article

References (70)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA. 2015; 65:87-108.
2. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M and La Vecchia C. Recent patterns in gastric cancer: a global overview. International journal of cancer. 2009; 125:666-673.
3. Clapp RW, Jacobs MM and Loechler EL. Environmental and occupational causes of cancer: new evidence 2005-2007 Reviews on environmental health. 2008; 23:1-37.
4. Coussens LM and Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867.
5. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB and Kim HC. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clinical cancer research. 2000; 6:519-525.
6. Wang Z, Chen JQ and Liu JL. COX-2 Inhibitors and Gastric Cancer. Gastroenterology research and practice. 2014; 2014:132320.
7. Bertuccio P, Bravi F, Bosetti C, Negri E and La Vecchia C. Aspirin and gastric cancer risk. European journal of cancer prevention. 2010; 19:426-427.
8. Cook NR, Lee IM, Zhang SM, Moorthy MV and Buring JE. Alternate-day, low-dose aspirin and cancer risk: longterm observational follow-up of a randomized trial. Annals of internal medicine. 2013; 159:77-85.
9. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ and Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. Journal of clinical oncology. 2010; 28:2952-2957.
10. Wang Y, Shen C, Ge J and Duan H. Regular aspirin use and stomach cancer risk in China. European journal of surgical oncology. 2015; 41:801-804.
11. Tian W, Zhao Y, Liu S and Li X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. European journal of cancer prevention. 2010; 19:288-298.
12. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR and Schatzkin A. Non-steroidal antiinflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a metaanalysis. British journal of cancer. 2009; 100:551-557.
13. Bosetti C, Rosato V, Gallus S, Cuzick J and La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Annals of oncology. 2012; 23:1403-1415.
14. Ichikura T, Ogawa T, Kawabata T, Chochi K, Sugasawa H and Mochizuki H. Is adenocarcinoma of the gastric cardia a distinct entity independent of subcardial carcinoma? World journal of surgery. 2003; 27:334-338.
15. Cho Y, Lee DH, Oh HS, Seo JY, Lee DH, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jung HC, Yoon YB and Song IS. Higher prevalence of obesity in gastric cardia adenocarcinoma compared to gastric non-cardia adenocarcinoma. Digestive diseases and sciences. 2012; 57:2687-2692.
16. Xue L, Zhang X, Li Y, Yang H, Li X, Mi J, Wang H, Wang J and Yan X. Differences of immunophenotypic markers and signaling molecules between adenocarcinomas of gastric cardia and distal stomach. Human pathology. 2011; 42:594-601.
17. Kim YI, Kim SY, Kim JH, Lee JH, Kim YW, Ryu KW, Park JH and Choi IJ. Long-term Low-dose Aspirin use Reduces Gastric Cancer Incidence: A Nationwide Cohort Study. Cancer research and treatment. 2016; 48: 798-805.
18. Gong EJ, Ahn JY, Jung HY, Lim H, Choi KS, Lee JH, Kim do H, Choi KD, Song HJ, Lee GH, Kim JH, Choi SY, Choe JW and Kim MJ. Risk factors and clinical outcomes of gastric cancer identified by screening endoscopy: a casecontrol study. Journal of gastroenterology and hepatology. 2014; 29:301-309.
19. Jacobs EJ, Newton CC, Gapstur SM and Thun MJ. Daily aspirin use and cancer mortality in a large US cohort. Journal of the National Cancer Institute. 2012; 104:1208-1217.
20. Lee J, Lee SH, Hur KY, Woo SY, Kim SW and Kang WK. Statins and the risk of gastric cancer in diabetes patients. BMC cancer. 2012; 12:596.
21. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP and Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377:31-41.
22. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF, Jr. and Chow WH. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer causes & control. 2009; 20:361-368.
23. Epplein M, Nomura AM, Wilkens LR, Henderson BE and Kolonel LN. Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. American journal of epidemiology. 2009; 170:507-514.
24. Duan L, Wu AH, Sullivan-Halley J and Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer epidemiology, biomarkers & prevention. 2008; 17:126-134.
25. Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, Mujumdar U, Ownby D, Wells K, Yood MU and Engel LS. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clinical gastroenterology and hepatology. 2007; 5:1154-1159.e1153.
26. Trivers KF, De Roos AJ, Gammon MD, Vaughan TL, Risch HA, Olshan AF, Schoenberg JB, Mayne ST, Dubrow R, Stanford JL, Abrahamson P, Rotterdam H, West AB, Fraumeni JF and Chow WH. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clinical gastroenterology and hepatology. 2005; 3:225-230.
27. Lindblad M, Lagergren J and Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer epidemiology, biomarkers & prevention. 2005; 14:444-450.
28. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR and Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer research. 2004; 24:3177-3184.
29. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A and Baron JA. Risk of cancer in a large cohort of nonaspirin NSAID users: a populationbased study. British journal of cancer. 2003; 88:1687-1692.
30. Nomura AM, Hankin JH, Kolonel LN, Wilkens LR, Goodman MT and Stemmermann GN. Case-control study of diet and other risk factors for gastric cancer in Hawaii (United States). Cancer causes & control. 2003; 14:547-558.
31. Akre K, Ekstrom AM, Signorello LB, Hansson LE and Nyren O. Aspirin and risk for gastric cancer: a populationbased case-control study in Sweden. British journal of cancer. 2001; 84:965-968.
32. Langman MJ, Cheng KK, Gilman EA and Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000; 320:1642-1646.
33. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD and Shapiro S. Nonsteroidal antiinflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer epidemiology, biomarkers & prevention. 2000; 9:119-123.
34. Zaridze D, Borisova E, Maximovitch D and Chkhikvadze V. Aspirin protects against gastric cancer: results of a casecontrol study from Moscow, Russia. International journal of cancer. 1999; 82:473-476.
35. Thun MJ, Namboodiri MM, Calle EE, Flanders WD and Heath CW, Jr. Aspirin use and risk of fatal cancer. Cancer research. 1993; 53:1322-1327.
36. de Pedro M, Baeza S, Escudero MT, Dierssen-Sotos T, Gomez-Acebo I, Pollan M and Llorca J. Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast cancer research and treatment. 2015; 149:525-536.
37. Friis S, Riis AH, Erichsen R, Baron JA and Sorensen HT. Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. Annals of internal medicine. 2015; 163:347-355.
38. Lapi F, Levi M, Simonetti M, Cancian M, Parretti D, Cricelli I, Sobrero A and Cricelli C. Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study. International journal of cancer. 2016; 139:205-211.
39. Jana NR. NSAIDs and apoptosis. Cellular and molecular life sciences. 2008; 65:1295-1301.
40. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H and Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. Journal of clinical gastroenterology. 1998; 27 Suppl 1:S47-52.
41. Nam KT, Hahm KB, Oh SY, Yeo M, Han SU, Ahn B, Kim YB, Kang JS, Jang DD, Yang KH and Kim DY. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clinical cancer research. 2004; 10:8105-8113.
42. Jiang XH and Wong BC. Cyclooxygenase-2 inhibition and gastric cancer. Current pharmaceutical design. 2003; 9:2281-2288.
43. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ and Pamukcu R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer research. 1997; 57:2909-2915.
44. Kopp E and Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994; 265:956-959.
45. Yamamoto Y, Yin MJ, Lin KM and Gaynor RB. Sulindac inhibits activation of the NF-kappaB pathway. The Journal of biological chemistry. 1999; 274:27307-27314.
46. Elwood PC, Gallagher AM, Duthie GG, Mur LA and Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009; 373:1301-1309.
47. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK and Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? British journal of cancer. 2011; 105:1107-1113.
48. Wang WH, Wong WM, Dailidiene D, Berg DE, Gu Q, Lai KC, Lam SK and Wong BC. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut. 2003; 52:490-495.
49. Sawaoka H, Kawano S, Tsuji S, Tsuji M, Sun W, Gunawan ES and Hori M. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins, leukotrienes, and essential fatty acids. 1998; 59:313-316.
50. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF, Jr. and Blot WJ. Use of aspirin and other nonsteroidal antiinflammatory drugs and risk of esophageal and gastric cancer. Cancer epidemiology, biomarkers & prevention. 1998; 7:97-102.
51. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC, Albanes D, Virtamo J and Taylor PR. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. Journal of the National Cancer Institute. 2006; 98:1445-1452.
52. Cavaleiro-Pinto M, Peleteiro B, Lunet N and Barros H. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer causes & control. 2011; 22:375-387.
53. Ratnasinghe D, Tangrea JA, Roth MJ, Dawsey SM, Anver M, Kasprzak BA, Hu N, Wang QH and Taylor PR. Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus. Oncology reports. 1999; 6:965-968.
54. Hwang D, Scollard D, Byrne J and Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. Journal of the National Cancer Institute. 1998; 90:455-460.
55. Tsuji S, Tsujii M, Kawano S and Hori M. Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. Journal of experimental & clinical cancer research. 2001; 20:117-129.
56. Ye X, Fu J, Yang Y and Chen S. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a metaanalysis of published cohort studies. PloS one. 2013; 8:e57578.
57. Xiaohua Y, Zhenjiang Y, Weidong L, Pengcheng X and Sidong C. The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis. Pharmacoepidemiology and drug safety. 2014; 23:278-284.
58. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001; 119(1 Suppl):39S-63S.
59. Oshima T, Miwa H and Joh T. Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin-7. American journal of physiology Cell physiology. 2008; 295:C800-806.
60. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. European journal of epidemiology. 2010; 25:603-605.
61. Zhang J and Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. Jama. 1998; 280:1690-1691.
62. Greenland S and Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. American journal of epidemiology. 1992; 135:1301-1309.
63. Orsini N BR, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata Journal. 2006; 6:40-57.
64. Berlin JA, Longnecker MP and Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology. 1993; 4:218-228.
65. Orsini N, Li R, Wolk A, Khudyakov P and Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. American journal of epidemiology. 2012; 175:66-73.
66. Bagnardi V, Zambon A, Quatto P and Corrao G. Flexible metaregression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. American journal of epidemiology. 2004; 159:1077-1086.
67. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003; 327:557-560.
68. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997; 315:629-634.
69. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-1101.
70. Duval S and Tweedie R. Trim and fill: A simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56:455-463.